Table 3.
Variables | Events/Evaluable | Hazard Ratio (95% confidence interval) |
p-value |
---|---|---|---|
Overall Mortality* | |||
KIR ligand matched | 66/114 | 1.00 | |
KIR ligand mismatched | 51/85 | 0.95 (0.66 – 1.37) | 0.79 |
Treatment failure** | |||
KIR ligand matched | 71/113 | 1.00 | |
KIR ligand mismatched | 52/85 | 0.87 (0.61 – 1.25) | 0.45 |
Relapse*** | |||
KIR ligand matched | 45/113 | 1.00 | |
KIR ligand mismatched | 37/85 | 0.96 (0.61 – 1.51) | 0.87 |
NRM | |||
KIR ligand matched | 26/113 | 1.00 | |
KIR ligand mismatched | 15/85 | 0.69 (0.36 – 1.30) | 0.25 |
Grade 2–4 acute GVHD# | |||
KIR ligand matched | 40/114 | 1.00 | |
KIR ligand mismatched | 30/85 | 0.99 (0.61 – 1.60) | 0.97 |
Chronic GVHD## | |||
KIR ligand matched | 15/114 | 1.00 | |
KIR ligand mismatched | 21/85 | 1.66 (0.85 – 3.24) | 0.14 |
Model adjusted for disease status (CR2 vs. CR1 HR 1.91, 95% CI 1.15 – 3.19, p=0.01; relapse vs. CR1 HR 4.82, 95% CI 3.01 – 7.71, p<0.0001)
Model adjusted for disease status (CR2 vs. CR1 HR 1.91, 95% CI 1.15 – 3.19, p=0.01; relapse vs. CR1 HR 4.82, 95% CI 3.01 – 7.71, p<0.0001)
Model adjusted for disease status (CR2 vs. CR1 HR 2.80, 95% CI 1.40 – 5.58, p=0.004; relapse vs. CR1 HR 10.04, 95% CI 5.31 – 19.00, p<0.0001); sex (male vs. female HR 1.68, 95% CI 1.08 – 2.63, p=0.02)
Model adjusted for in vivo T-cell depletion vs. none (HR 1.79, 95% CI 1.07 – 3.01, p=0.03); patient age (>16 vs. ≤16 years HR 0.50, 95% CI 0.27 – 0.91, p=0.02)
Model adjusted for in vivo T-cell depletion vs. none (HR 2.35, 95% CI 1.20 – 4.58, p=0.01)